- €189.42m
- €98.76m
- €6.86m
French and Benelux stocks-Factors to watch on Friday
Brief: Transgene To Present Updated Positive Preliminary Data From Phase I Clinical Trials With TG4050 (Myvac Platform) At ASCO 2022
Brief: Transgene Q1 Cash And Cash Equivalents At EUR 46.8 Mln
Brief: Transgene To Present New Positive Preliminary Phase I Clinical Data For TG4050
Brief: Transgene Proposes Appointment Of Dr. Alessandro Riva As Independent Chairman
Brief: Transgene Expects Significant Clinical Results In 2022
Brief: Transgene To Present New Positive Preliminary Phase I Data On Tg4050 At AACR 2022
Brief: Transgene And BioInvent Joint JITC Publication Shows Potential Of BT-001 Oncolytic Virus
Brief: Transgene, PersonGen Partner On Therapy Against Solid Tumors
Transgene jumps as AstraZeneca exercises option for its oncolytic virus candidate
Brief: Transgene: Astrazeneca Has Exercised Its First License Option for An Invir.IO Oncolytic Virus
Brief: Transgene, NEC Announce Positive Preliminary Data From TG4050 Studies
Brief: Transgene/BioInvent: positive data regarding their BT-001 product
Brief: Transgene Q3 Operating Income Down At 1.8 Million Euros
Brief: Transgene Says Financial Visibility Extended Until End 2023
Brief: Transgene Says Data From Phase I Trial Shows TG6002 Has Potential For IV Administration
Brief: Medesis Pharma And Transgene Announce Joint European Patent
Brief: Transgene Updates On TG4050 Phase I Trial
Brief: Transgene Updates On Phase II Clinical Trial Of TG4001 + Avelumab Versus Avelumab Alone